News & analysis, rated.
Breaking AI developments, in-depth guides, real-world case studies, and analysis — each one rated so you know what matters.
Incyte to buy Star for up to $2B in blood disorder push
Incyte is nearing a deal to acquire blood disorder biotech Star for up to $2 billion. The move expands the pharma company's pipeline in hematology and rare blood conditions.
Bending Spoons files US IPO, bringing AOL and Vimeo public
Bending Spoons, the Italian software company that owns AOL and Vimeo, has filed for a US initial public offering. The move marks a major consolidation play in digital media and consumer software.
Bybit opens SpaceX tokenized IPO access to crypto traders
Cryptocurrency exchange Bybit is now offering tokenized access to SpaceX's IPO through its platform. The move signals how traditional asset tokenization is reaching retail traders via crypto exchanges.
SpaceX breaks five Wall Street IPO rules—here's what changed
Reuters reports Elon Musk's SpaceX is sidestepping traditional IPO playbook steps. Learn which five conventions the aerospace firm abandoned and why investors are watching.
SpaceX IPO: how retail investors can buy shares
SpaceX has not yet filed for an IPO, but Reuters explores the mechanics retail investors would face if Elon Musk's company goes public. Here's what you need to know.
Casepoint Names GovTech Veteran Paul Colangelo as CEO
Paul Colangelo, founder of government software firm Neumo, takes the helm of Casepoint after Thoma Bravo's January 2025 acquisition and merger with OPEXUS. The move signals focus on state and local government markets.
Four legal AI vendors adopt Model Context Protocol in weeks
Definely, iManage, NetDocuments, and LexSoft T3 all moved to MCP compatibility nearly simultaneously. For law firms, the question is no longer what a tool does—it's how it plugs into your existing workflow.
3 million Wegovy pills filled as GLP-1 obesity drug expands
Novo Nordisk reports 3 million Wegovy oral prescriptions filled, with one dispensed every 5 seconds. The company presented new data at ADA 2026 on reaching previously untreated patients.
Oncopeptides enrolls first patient in German real-world multiple myeloma study
Oncopeptides has started its Marina study across 25 German clinical sites to track Pepaxti's performance in routine multiple myeloma care. The 50-patient trial will measure outcomes beyond controlled trials.
Survodutide cuts visceral fat 34%, liver fat 63% in phase 3 obesity trial
Boehringer Ingelheim's dual glucagon/GLP-1 agonist achieved up to 16.6% weight loss in 76-week trial, with separate analysis showing metabolic benefits beyond the scale.
EU approves IntraBio's Aqneursa for rare neurological disease NPC
The European Commission granted marketing authorisation for levacetylleucine to treat Niemann-Pick disease type C in patients aged six and above. Phase III data showed 118% reduction in annual disease progression.
Sanofi Licenses Owkin AI Platform for Drug Discovery Agents
Sanofi extends its five-year partnership with Owkin to deploy custom agentic AI tools across drug development. The move builds on a €90m collaboration launched in 2021 focused on oncology and immunology pipelines.